JP2020529457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529457A5 JP2020529457A5 JP2020506940A JP2020506940A JP2020529457A5 JP 2020529457 A5 JP2020529457 A5 JP 2020529457A5 JP 2020506940 A JP2020506940 A JP 2020506940A JP 2020506940 A JP2020506940 A JP 2020506940A JP 2020529457 A5 JP2020529457 A5 JP 2020529457A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- nhr
- linker
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 238000000034 method Methods 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17185598 | 2017-08-09 | ||
| EP17185598.4 | 2017-08-09 | ||
| PCT/EP2018/071507 WO2019030284A1 (en) | 2017-08-09 | 2018-08-08 | NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529457A JP2020529457A (ja) | 2020-10-08 |
| JP2020529457A5 true JP2020529457A5 (enExample) | 2021-09-24 |
| JP7218351B2 JP7218351B2 (ja) | 2023-02-06 |
Family
ID=59579518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506940A Active JP7218351B2 (ja) | 2017-08-09 | 2018-08-08 | 新たな標的化された細胞傷害性ラトジャドン誘導体及びそのコンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11236059B2 (enExample) |
| EP (1) | EP3665161B1 (enExample) |
| JP (1) | JP7218351B2 (enExample) |
| AU (1) | AU2018315154B2 (enExample) |
| CA (1) | CA3072399A1 (enExample) |
| WO (1) | WO2019030284A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022530823A (ja) * | 2019-05-02 | 2022-07-01 | ザ・ユニバーシティ・オブ・シドニー | がん治療のためのペプチド誘導体とそのコンジュゲート |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| DE69112684T2 (de) * | 1990-04-06 | 1996-02-01 | Univ Tulane | LHRH-Analoge. |
| DE19636721A1 (de) | 1996-09-10 | 1998-03-12 | Biotechnolog Forschung Gmbh | Antibiotische und antitumorale Verbindung, Herstellungsverfahren, Mittel und DSM 11 071 |
| DE10106647A1 (de) | 2001-02-12 | 2002-08-22 | Univ Hannover | Ratjadon-Derivate zum Hemmen des Zellwachstums |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7446196B2 (en) | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| TWI411451B (zh) | 2006-06-01 | 2013-10-11 | Msd Consumer Care Inc | 用於結腸吸收之脫羥腎上腺素醫藥調配物及組合物 |
| EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6855661B2 (ja) | 2012-10-23 | 2021-04-07 | シンアフィックス ビー．ブイ． | 修飾抗体、抗体コンジュゲート及びそれらを調製する方法 |
| ES2819573T3 (es) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A |
| KR20160035600A (ko) | 2013-08-02 | 2016-03-31 | 사노피 | 고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도 |
-
2018
- 2018-08-08 EP EP18749385.3A patent/EP3665161B1/en active Active
- 2018-08-08 AU AU2018315154A patent/AU2018315154B2/en active Active
- 2018-08-08 CA CA3072399A patent/CA3072399A1/en active Pending
- 2018-08-08 WO PCT/EP2018/071507 patent/WO2019030284A1/en not_active Ceased
- 2018-08-08 US US16/637,257 patent/US11236059B2/en active Active
- 2018-08-08 JP JP2020506940A patent/JP7218351B2/ja active Active